GlassScriptPhysician profile
Bethany A Templin
NPI 1609259373
$4,711.32
in general payments reported to CMS, 2019-2025
38 companies · $736 in 2025
The $736 reported for 2025 was more than what 82% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $679 · 2023: $1,265 · 2024: $1,341 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $626.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $519.67 | 2021-2025 | |
| Pfizer INC. | $415.35 | 2021-2025 | |
| Novo Nordisk INC | $341.72 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $299.70 | 2021-2022 | |
| Astellas Pharma US INC | $299.62 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.46 | 2022-2025 | Xifaxan |
| Corcept Therapeutics | $220.58 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $209.70 | 2021-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $177.01 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $168.03 | 2022-2025 | Farxiga, Seroquel, Flumist Quadrivalent |
| Xeris Pharmaceuticals, INC. | $132.47 | 2025 | Gvoke Hypopen, Recorlev |
| E.R. Squibb & Sons, L.L.C. | $125.97 | 2022-2024 | Eliquis |
| Idorsia Pharmaceuticals US INC | $120.67 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $111.08 | 2022-2024 | Watchman Flx |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Templin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.